Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,053.68
(
-1.27%
)
News Focus
News Focus
Post# of 826320
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Lykiri

Send PM Follow Ignore
Followers 134
Posts 2197
Boards Moderated 0
Alias Born 11/22/2017

Lykiri

Re: Hopeforthefuture3 post# 728210

Thursday, 10/24/2024 7:33:20 PM

Thursday, October 24, 2024 7:33:20 PM

Post# of 826320
OCTOBER 23, 2024

INDIANAPOLIS, Oct. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for donanemab, an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in eligible adults in Great Britain


https://investor.lilly.com/news-releases/news-release-details/lillys-kisunlatm-donanemab-azbt-receives-marketing-authorization

OCTOBER 24, 2024

MHRA approves donanemab…
…but NICE says it does not demonstrate value for the NHS

.
https://acnr.co.uk/mhra-approves-donanemab/
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News